BRPI0414858A - métodos para preparação de corpos de óleo compreendendo ingredientes ativos - Google Patents

métodos para preparação de corpos de óleo compreendendo ingredientes ativos

Info

Publication number
BRPI0414858A
BRPI0414858A BRPI0414858-4A BRPI0414858A BRPI0414858A BR PI0414858 A BRPI0414858 A BR PI0414858A BR PI0414858 A BRPI0414858 A BR PI0414858A BR PI0414858 A BRPI0414858 A BR PI0414858A
Authority
BR
Brazil
Prior art keywords
methods
oil bodies
active ingredients
preparing oil
emulsions
Prior art date
Application number
BRPI0414858-4A
Other languages
English (en)
Inventor
Elizabeth Wanda Murray
Joseph Boothe
Nancy-Ann Markley
Original Assignee
Sembiosys Genetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sembiosys Genetics Inc filed Critical Sembiosys Genetics Inc
Publication of BRPI0414858A publication Critical patent/BRPI0414858A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A61K36/286—Carthamus (distaff thistle)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/04—Dispersions; Emulsions
    • A61K8/06—Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A61P23/02—Local anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Botany (AREA)
  • Anesthesiology (AREA)
  • Birds (AREA)
  • Emergency Medicine (AREA)
  • Mycology (AREA)
  • Medical Informatics (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Nutrition Science (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Cosmetics (AREA)
  • Colloid Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

"MéTODOS PARA PREPARAçãO DE CORPOS DE óLEO COMPREENDENDO INGREDIENTES ATIVOS". A presente invenção provê emulsões que compreendem corpos de óleo. A invenção refere-se também a métodos para geração de formulações compreendendo corpos de óleo como ingredientes ativos, onde o ingrediente ativo é dividido dentro de corpos de óleo. Os métodos são particularmente úteis para geração de emulsões com agentes biologicamente ativos hidrofóbicos ou anfifáticos.
BRPI0414858-4A 2003-10-02 2004-10-04 métodos para preparação de corpos de óleo compreendendo ingredientes ativos BRPI0414858A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US50750503P 2003-10-02 2003-10-02
PCT/CA2004/001792 WO2005030169A1 (en) 2003-10-02 2004-10-04 Methods for preparing oil bodies comprising active ingredients

Publications (1)

Publication Number Publication Date
BRPI0414858A true BRPI0414858A (pt) 2006-11-21

Family

ID=34393238

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0414858-4A BRPI0414858A (pt) 2003-10-02 2004-10-04 métodos para preparação de corpos de óleo compreendendo ingredientes ativos

Country Status (9)

Country Link
US (1) US20070196914A1 (pt)
EP (1) EP1670434A4 (pt)
JP (1) JP2007507432A (pt)
CN (1) CN1863506A (pt)
AU (1) AU2004275451B2 (pt)
BR (1) BRPI0414858A (pt)
CA (1) CA2539486A1 (pt)
EA (1) EA011856B1 (pt)
WO (1) WO2005030169A1 (pt)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101395370B1 (ko) 2004-01-22 2014-05-14 유니버시티 오브 마이애미 국소용 코-엔자임 큐10 제형 및 그의 사용 방법
EP2067475A4 (en) 2006-09-26 2010-12-15 Astellas Pharma Inc PREPARATION FOR TACROLIMUS MAINTAINED RELEASE
US20090011018A1 (en) 2006-12-28 2009-01-08 Astellas Pharma Inc., Sustained release formulation for tacrolimus
MX337408B (es) 2007-03-22 2016-03-03 Berg Llc Formulaciones topicas que tienen biodisponibilidad aumentada.
WO2009089115A1 (en) * 2008-01-04 2009-07-16 Hormel Foods Corporation Encapsulation of oxidatively unstable compounds
US20110020519A1 (en) * 2008-01-04 2011-01-27 Aveka, Inc. Encapsulation of oxidatively unstable compounds
MX2010011032A (es) 2008-04-11 2011-03-01 Cytotech Labs Llc Star Metodos y uso de induccion de apoptosis en celulas cancerigenas.
CA2720755A1 (en) * 2008-04-11 2009-10-15 Sembiosys Genetics, Inc. Controlled release of active agents from oleosomes
WO2010007553A2 (en) * 2008-07-15 2010-01-21 Tropical Sky Trading 156 Cc A composition
US9445975B2 (en) 2008-10-03 2016-09-20 Access Business Group International, Llc Composition and method for preparing stable unilamellar liposomal suspension
EP2228052A1 (en) 2009-03-09 2010-09-15 Coty Deutschland GmbH Cosmetic basic composition and use thereof
CN102481271A (zh) 2009-05-11 2012-05-30 博格生物系统有限责任公司 利用表观代谢转变剂、多维细胞内分子或环境影响剂治疗代谢障碍的方法
SG10202010355PA (en) 2010-03-12 2020-11-27 Berg Llc Intravenous formulations of coenzyme q10 (coq10) and methods of use thereof
CA2832324C (en) 2011-04-04 2022-03-15 Berg Llc Methods of treating central nervous system tumors
EP2720680B1 (en) 2011-06-17 2020-02-12 Berg LLC Inhalable pharmaceutical compositions
NZ713868A (en) 2013-04-08 2021-12-24 Berg Llc Treatment of cancer using coenzyme q10 combination therapies
CA2920835A1 (en) 2013-08-20 2015-02-26 Anutra Medical, Inc. Syringe fill system and method
KR102370843B1 (ko) 2013-09-04 2022-03-04 버그 엘엘씨 코엔자임 q10의 연속주입에 의한 암치료 방법
USD774182S1 (en) 2014-06-06 2016-12-13 Anutra Medical, Inc. Anesthetic delivery device
USD750768S1 (en) 2014-06-06 2016-03-01 Anutra Medical, Inc. Fluid administration syringe
USD763433S1 (en) 2014-06-06 2016-08-09 Anutra Medical, Inc. Delivery system cassette
HRP20201333T1 (hr) 2015-10-15 2020-11-27 Cargill, Incorporated Kompozicija koja sadrži oleosome sa različitom raspodjelom veličina
WO2017087576A1 (en) 2015-11-16 2017-05-26 Berg Llc Methods of treatment of temozolomide-resistant glioma using coenzyme q10
CN106902535B (zh) * 2015-12-23 2019-05-07 颖轩生技股份有限公司 活性原料的萃取制程
CN107312619A (zh) * 2017-07-25 2017-11-03 江苏省农业科学院 一种提高核桃仁油体提取完整度的方法
CA3124427C (en) * 2018-12-21 2023-11-28 Botaneco Inc. Cannabinoid formulations and methods of making same
WO2021097230A1 (en) * 2019-11-15 2021-05-20 Xylome Corporation Lipid body compositions, products made therefrom, methods of making same, and methods of use
US20260090577A1 (en) * 2022-09-28 2026-04-02 Cargill, Incorporated Oleosome composition with bio-actives

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5916596A (en) * 1993-02-22 1999-06-29 Vivorx Pharmaceuticals, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
US5616330A (en) * 1994-07-19 1997-04-01 Hemagen/Pfc Stable oil-in-water emulsions incorporating a taxine (taxol) and method of making same
US5856452A (en) * 1996-12-16 1999-01-05 Sembiosys Genetics Inc. Oil bodies and associated proteins as affinity matrices
BR9809691A (pt) * 1997-05-27 2000-10-03 Sembiosys Genetics Inc Usos de substâncias de óleo
US7585645B2 (en) * 1997-05-27 2009-09-08 Sembiosys Genetics Inc. Thioredoxin and thioredoxin reductase containing oil body based products
US6372234B1 (en) * 1997-05-27 2002-04-16 Sembiosys Genetics Inc. Products for topical applications comprising oil bodies
US6761914B2 (en) * 1997-05-27 2004-07-13 Sembiosys Genetics Inc. Immunogenic formulations comprising oil bodies
CA2376849C (en) * 1999-06-24 2008-10-14 Kyowa Hakko Kogyo Co., Ltd. Method of inhibiting leakage of drug encapsulated in liposomes
ATE440593T1 (de) * 2001-03-27 2009-09-15 Phares Pharm Res Nv Verfahren und zusammensetzung zur solubilisierung einer biologisch wirksamen verbindung mit geringer wasserlíslichkeit

Also Published As

Publication number Publication date
EP1670434A4 (en) 2010-06-23
WO2005030169A1 (en) 2005-04-07
AU2004275451B2 (en) 2010-11-25
JP2007507432A (ja) 2007-03-29
AU2004275451A1 (en) 2005-04-07
EA011856B1 (ru) 2009-06-30
CA2539486A1 (en) 2005-04-07
US20070196914A1 (en) 2007-08-23
CN1863506A (zh) 2006-11-15
EA200600686A1 (ru) 2006-08-25
EP1670434A1 (en) 2006-06-21
WO2005030169A8 (en) 2006-05-04

Similar Documents

Publication Publication Date Title
BRPI0414858A (pt) métodos para preparação de corpos de óleo compreendendo ingredientes ativos
HN1999000080A (es) Derivados de isotiazol utiles como agentes anticancerosos.
BRPI0511071A (pt) ácidos 3'-alcóxi tetrámicos e tetrÈnicos espirocìclicos
BR0215052A (pt) Composições acaricidas e métodos
PA8609701A1 (es) [1,8]naftiridin-2-onas y compuestos relacionados para el tratamiento de la esquizofrenia
BRPI0407950A (pt) processo para a preparação de uma composição de higiene pessoal
ATE415817T1 (de) Agrochemische formulierungen
CR8257A (es) Construcciones de union y metodos para uso de ellas
AR028948A1 (es) Compuestos novedosos
AR011539A1 (es) DERIVADOS DE BENZOILO-3-HETEROCICLIL-SUSTITUIDOS, PROCEDIMIENTO PARA SU PREPARACIoN,COMPUESTOS INTERMEDIARIOS DE APLICACIoN EN DICHO PROCEDIMIENTO, COMPOSICIONES QUE COMPRENDEN DICHOS DERIVADOS, Y PROCEDIMIENTO PARA SU PREPARACIoN, PROCEDIMIENTO PARA COMBATIR VEGETACIoN NO DESADA QUE LOS EMPLEA Y SU
ECSP045139A (es) DERIVADOS DE ACETILENO QUE TIENEN ACTIVIDAD ANTAGONISTICA DE MGluR5
PA8553101A1 (es) Formulaciones en combinacion de derivados de propanol-amina sustituidos con arilo, junto con otras sustancias activas y su utilizacion
ES2165523T3 (es) Derivados de la ciclopentano-1,3-diona.
BRPI0407181A (pt) Formulação farmacêutica
CO5221025A1 (es) 4-trifluorometil-3-oxazolilpiridinas, procedimiento para su preparacion, agentes que las contienen y su uso como agente para la lucha contra organismos daninos
HN2002000365A (es) Lactamas como antagonistas de taquiquininas
PA8487701A1 (es) Derivados de 3,3-biarilpiperidina y 2,2-biarilmorfolina
ES2170759T3 (es) Derivados de galantamina, un procedimiento para su preparacion y su uso como medicamentos.
ECSP034754A (es) Derivados de beta-carbolina y su uso farmaceutico contra depresion y ansiedad
AR020563A1 (es) Compuestos (poli)tia-alquinoicos y sus derivados, composiciones que los incluyen y su utilizacion
ECSP044971A (es) Isoxazolopiridinonas y su uso en el tratamiento de enfermedad de parkinson
GT200800066A (es) Derivados de 9-cloro-15-deoxiprostaglandina, procedimiento para su preparacion y su uso como medicamento.
GT200500340A (es) Derivados de octahidropirrolo [3,4-c] pirrol
BR0015338A (pt) Benzoilciclohexanodionas e benzoilpirazóis, processos para a sua preparação e sua aplicação como herbicidas e reguladores do crescimento de plantas
UY29999A1 (es) "n-pirazinil-fenilsulfonamidas, procedimientos y compuestos intemedios utilizados en su preparacion, composiciones farmaceuticas que las contienen y aplicaciones"

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08L Patent application lapsed because of non payment of annual fee [chapter 8.12 patent gazette]

Free format text: REFERENTE AO NAO RECOLHIMENTO DAS 8A E 9A ANUIDADES.

B15K Others concerning applications: alteration of classification

Ipc: A61Q 19/00 (2006.01), A61K 8/06 (2006.01), A61K 9/

B08I Publication cancelled [chapter 8.9 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 8.12 NA RPI NO 2259 DE 22/04/2014 POR TER SIDO INDEVIDA.

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 8A, 9A, 10A, 11A, 12A, 13A, 14A, 15A E 16A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2602 DE 17-11-2020 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.